Soligenix Inc. Reports Q2 2025 Results with Progress in Rare Disease Treatments

Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare disease treatments, has reported its second-quarter results for 2025, showcasing significant progress in its late-stage pipeline. The company is on track to deliver top-line Phase 2a results for SGX302, a treatment for mild-to-moderate psoriasis, by the end of the year. Additionally, updates are expected from an investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL), with a confirmatory Phase 3 trial currently enrolling patients and results anticipated in 2026.

Further bolstering its pipeline, Soligenix completed a Phase 2a proof-of-concept study for SGX945 in Behçet’s Disease, meeting its primary objective of demonstrating biological efficacy. The company has also made strides in manufacturing, transferring the production of synthetic hypericin to the U.S. under its partnership with Sterling Pharma Solutions. These developments underscore Soligenix's commitment to addressing unmet medical needs in rare diseases.

Financially, the company reported a net loss of $2.7 million, or ($0.82) per share, in Q2 2025, compared to a net loss of $1.6 million in the previous year. This increase was attributed to higher research and development expenses, which rose to $1.7 million due to increased trial and manufacturing costs. Despite these challenges, Soligenix remains financially stable, with $5.1 million in cash as of June 30, 2025, and an additional $1.4 million raised on July 1, ensuring funding for operations into the first quarter of 2026.

For more detailed information on Soligenix's Q2 2025 results and its pipeline developments, visit https://ibn.fm/SsFsy. The company's advancements in rare disease treatments highlight its potential to make a significant impact in the biopharmaceutical industry, offering hope to patients with limited therapeutic options.